Key result
Oral anticoagulation was not associated with a reduced risk of recurrent thromboembolic events compared with antiplatelet therapy in AF patients with CKD and prior stroke (HR 0.89; 95% CI 0.73-1.09).
Why the study?
Oral anticoagulation as secondary stroke prophylaxis in atrial fibrillation patients with chronic kidney disease remains unexplored and poses a clinical treatment dilemma.
Does oral anticoagulation therapy reduce thromboembolic events in atrial fibrillation patients with chronic kidney disease and prior ischemic stroke compared to antiplatelet therapy?
Cohort (n=1,252)
Yes
Does oral anticoagulation therapy reduce thromboembolic events in atrial fibrillation patients with chronic kidney disease and prior ischemic stroke compared to antiplatelet therapy?
In AF patients with CKD and prior ischemic stroke, oral anticoagulation was not associated with a reduced risk of recurrent thromboembolic events compared to antiplatelet therapy.
No clear benefit of oral anticoagulation over antiplatelet therapy observed; leaves open optimal antithrombotic strategy in AF with CKD and prior stroke.
AIMS: Oral anticoagulation (OAC) therapy as secondary stroke prophylaxis in atrial fibrillation (AF) patients with chronic kidney disease (CKD) remains unexplored and poses a clinical treatment dilemma. We assessed the long-term risk of thromboembolic events according to post-stroke OAC therapy in AF patients with CKD after their first ischaemic stroke. METHODS AND RESULTS: We identified Danish AF patients with CKD who presented with first-time ischaemic stroke from 2005 to 2014. Chronic kidney disease was defined as a diagnosis code for CKD before baseline, defined as 100 days after stroke discharge. Post-stroke antithrombotic therapy (OAC therapy and antiplatelet therapy) was identified from prescription claims from discharge to baseline. Cumulative incidences and adjusted hazard ratios (HRs) of thromboembolic events according to post-stroke OAC therapy were examined. Of 1252 AF patients with CKD presenting with ischaemic stroke, 631 (50.4%) patients were on OAC therapy and 621 (49.6%) were on antiplatelet therapy alone at baseline [median age 76 (interquartile range, IQR 71-83) and 80 (IQR 72-86), respectively]. The median follow-up period was 1.9 years (IQR 0.8-3.6). Cumulative incidence rates of thromboembolic events and bleeding showed no significant difference between those on OAC therapy and antiplatelet therapy. The results from the multivariable analysis revealed similar results: thromboembolic risk was not modified by OAC treatment [adjusted HR 0.89, 95% confidence interval (CI) 0.73-1.09] nor was the risk of bleeding (adjusted HR 0.88, 95% CI 0.67-1.17). CONCLUSION: Oral anticoagulation in patients with CKD and prior stroke was not associated with a reduced risk of recurrent thromboembolic events compared with antiplatelet therapy.
No takes yet. Share an insight, caveat, or question.
Christensen et al. (2019) conducted a cohort in Atrial fibrillation with chronic kidney disease and prior ischaemic stroke (n=1,252). Oral anticoagulation (OAC) therapy vs. Antiplatelet therapy alone was evaluated on Thromboembolic events (adjusted HR 0.89, 95% CI 0.73-1.09). Oral anticoagulation was not associated with a reduced risk of recurrent thromboembolic events compared with antiplatelet therapy in AF patients with CKD and prior stroke (HR 0.89; 95% CI 0.73-1.09).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: